A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples